Women's Dermatologic Society

An Interview with Lawrence J Green, MD, FAAD Clinical Professor of Dermatology George Washington University School of Medicine Vice President Elect, American Academy of Dermatology Interviewed by Dr. Amaris Geisler and Dr. Brianna Olamiju  1.) How did you become involved in the WDS and what benefits do you think WDS membership provides for residents/young physicians? I started volunteering with the WDS about 10 years ago, when Dr Adelaide Hebert, who was part of my class on the AAD Board of Directors filled me on how important a role the WDS plays in dermatology. Before that, I never really appreciated the value the WDS adds to our field. Many/Most of the recent leaders in dermatology have come through the WDS. I believe this is because the WDS fosters not just collegiality among all dermatologists, but it also uniquely encourages and provides opportunities for young dermatologists (and dermatologists to be) to get involved in our field. The WDS also encourages and pr...

  Advances in Dermatology: 2024 in Review  By Cather McKay, MD The past year has been another exciting one in the field of dermatology! New medications and expanded indications give us more options than ever to care for our patients.   Atopic dermatitis and prurigo nodularis More topical options for atopic dermatitis (AD) became available this year with the approval of roflumilast 0.15% cream (Zoryve) in patients aged 6 years and up and tapinarof 1% cream (Vtama) in patients aged 2 years and up. 1,2 Approval of the pan-JAK inhibitor delgocitinib cream for adults with chronic hand eczema is expected based on phase 3 trials. 3 Ruxolitinib cream (Opzelura) is currently approved for ages 12 and up, but has shown safety and efficacy in patients as young as 2 years. 4 IL-13 inhibitor lebrikizumab (Ebglyss) was approved in September for moderate to severe AD in patients 12 years and up who weigh at least 40 kg. 5 Another IL-13 inhibitor, cendakimab, is in develo...

  Melanoma: Recent Advances and Future Possibilities By Cather McKay MD, FAAD The incidence of invasive melanoma increases each year. Deaths from melanoma steadily rose until 2014, decreased until 2019, but have been on the rise again. As of 2024, the American Cancer Society predicts the lifetime risk of melanoma is 1 in 33 for White Americans, 1 in 1,000 for Black Americans, and 1 in 200 for Hispanic Americans. 1 Despite lower incidence in patients with skin of color, diagnosis tends to occur later with poorer survival as a result. We as dermatologists aim to improve diagnostic accuracy and correctly stage our patients so they can be referred to appropriate specialists. Melanoma staging and National Comprehensive Cancer Network (NCCN) guidelines are important for every dermatologist to review and are available with a free NCCN account. Here are some of the recent updates 2 :   Biopsy principles Biopsy via saucerization/deep shave removal, punch for small dia...